Swiss pharma takes option on FXR agonist emricasan.
Genfit was among a group of NASH companies publishing updates at the International Liver Congress.
NHS patients to get access to drug in PBC.
Potential liver blockbuster gets EU licence.
But drug flops in two other indications.
Sales forecast to reach $2.6 billion in 2020.